PDF Cover

Romiplostim Market

The market for Romiplostim was estimated at $1.5 billion in 2025; it is anticipated to increase to $2.2 billion by 2030, with projections indicating growth to around $3.3 billion by 2035.

Report ID:DS1802425
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Romiplostim
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Romiplostim Market Outlook

Revenue, 2025

$1.5B

Forecast, 2035

$3.3B

CAGR, 2026 - 2035

8.6%

The Romiplostim industry revenue is expected to be around $1.6 billion in 2026 and expected to showcase growth with 8.6% CAGR between 2026 and 2035. Building on this trajectory, the romiplostim market is gaining strong clinical and commercial significance due to the rising global burden of chronic immune thrombocytopenia and increasing reliance on targeted biologic therapies. Growing awareness among healthcare providers regarding advanced treatment options for platelet disorders is further strengthening adoption. Improved diagnostic rates, expanding healthcare access in emerging economies, and supportive reimbursement frameworks in developed markets are also contributing to sustained demand. Additionally, the shift toward long-term disease management rather than short-term symptomatic treatment is reinforcing the relevance of thrombopoietin receptor agonists in modern hematology practice.

Romiplostim, also known as Nplate, is a thrombopoietin receptor agonist used primarily to stimulate platelet production in patients with chronic immune thrombocytopenia, particularly when first-line therapies fail or are insufficient. It is administered as a subcutaneous injection and works by activating megakaryocyte proliferation in the bone marrow, thereby increasing platelet counts and reducing bleeding risks. Its key applications include treatment of adult and pediatric patients with chronic ITP and cases where splenectomy or other therapies are ineffective. Recent trends show increasing adoption due to favorable clinical outcomes, improved patient response rates, and growing physician preference for biologic-based targeted therapies. Ongoing research into broader hematological applications and long-term safety optimization is further supporting market expansion and clinical acceptance globally.

Romiplostim market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Romiplostim Market Outlook

Market Key Insights

  • The Romiplostim market is projected to grow from $1.5 billion in 2025 to $3.3 billion in 2035. This represents a CAGR of 8.6%, reflecting rising demand across Chronic Immune Thrombocytopenia Management, Pediatric Immune Thrombocytopenia Treatment, and Hepatitis C-Associated Thrombocytopenia.

  • The market exhibits an oligopolistic structure with only 4 prominent players, with Amgen Inc. and Intas Pharmaceuticals commanding the largest shares.

  • U.S. and Japan are the top markets within the Romiplostim market and are expected to observe the growth CAGR of 6.3% to 9.0% between 2025 and 2030.

  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.3% to 10.8%.

  • Slow adoption of Shift from conventional immunosuppressive therapies to targeted biologic platelet stimulation treatments transition within key players in Romiplostim market is creating a revenue window for adjacent and alternate markets like Eltrombopag and Avatrombopag to improve its use-case penetration in Chronic Immune Thrombocytopenia and Off-level Use applications and expected to capture $101 million revenue from existing Romiplostim market.

  • The Romiplostim market is set to add $1.9 billion between 2025 and 2035, with manufacturer targeting Off-level Use Application projected to gain a larger market share.

  • With

    increased prevalence of blood-related diseases, and

    Advancements in Biotechnology Sector, Romiplostim market to expand 128% between 2025 and 2035.

romiplostim market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Romiplostim - Country Share Analysis

Opportunities in the Romiplostim

An emerging opportunity for romiplostim is also its use in hepatitis C-associated thrombocytopenia, where low platelet counts restrict antiviral treatment eligibility. By increasing platelet levels, romiplostim enables safer initiation and continuation of antiviral therapies, including direct-acting antivirals. This is particularly important in patients with advanced liver disease or cirrhosis, where treatment options are limited. Increasing global hepatitis C screening programs and expanding access to antiviral therapies are indirectly boosting demand for supportive treatments like romiplostim. This application is gaining traction in regions with high hepatitis burden, including parts of Asia-Pacific, the Middle East, and Eastern Europe.

Growth Opportunities in North America and Europe

North America is a leading market for romiplostim, driven by high prevalence of chronic immune thrombocytopenia, strong healthcare infrastructure, and early adoption of biologic therapies. The United States dominates regional demand due to advanced hematology care, favorable reimbursement policies, and widespread use of thrombopoietin receptor agonists in clinical practice. Key opportunities include expanded use in pediatric ITP treatment and long-term outpatient disease management programs. Competition is moderate to high, with established pharmaceutical players focusing on biologic innovation and lifecycle management strategies. Strong physician awareness and established treatment guidelines further support adoption. Additionally, increasing focus on precision medicine and improved diagnosis rates are reinforcing steady demand across hospitals and specialty care centers.
Europe represents a significant market for romiplostim, supported by structured healthcare systems, increasing diagnosis of immune thrombocytopenia, and growing acceptance of biologic therapies. Countries such as Germany, the United Kingdom, and France are key contributors due to strong hematology networks and supportive clinical guidelines. Opportunities are emerging in chronic ITP management and expanding use in pediatric and secondary thrombocytopenia cases. Competition is influenced by the presence of alternative thrombopoietin receptor agonists and strict pricing regulations under public healthcare systems. Demand is driven by increasing preference for targeted therapies and improved patient outcomes. However, cost containment policies and reimbursement frameworks play a critical role in shaping market access and adoption rates across the region.

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of immune thrombocytopenia and expanding biologic treatment adoption globally

The growth of the romiplostim market is also strongly driven by the increasing prevalence of immune thrombocytopenia and the expanding adoption of biologic therapies. Rising diagnosis rates of chronic ITP across both adult and pediatric populations are also creating a larger patient pool requiring long-term platelet management solutions. At the same time, clinicians are also shifting away from conventional immunosuppressive treatments toward targeted biologics like thrombopoietin receptor agonists due to improved efficacy and safety profiles. This transition is also further supported by better disease awareness, improved diagnostic infrastructure, and growing preference for precision medicine approaches in hematology, collectively strengthening demand for romiplostim.
A key driver for romiplostim is also the increasing clinical preference for thrombopoietin receptor agonists within standard hematology treatment protocols. Physicians are also increasingly adopting romiplostim due to its ability to stimulate endogenous platelet production, offering a targeted and sustained therapeutic response in chronic immune thrombocytopenia. Its integration into treatment guidelines for patients who are also refractory to first-line therapies has also significantly expanded its clinical use. Additionally, growing evidence supporting long-term safety and effectiveness is also encouraging broader prescription practices. This shift toward biologic-based platelet management is also accelerating adoption across hospitals and specialty care centers globally.
02

Restraint: High treatment cost and limited reimbursement coverage restricting patient access globally

One of the most significant restraints for the romiplostim market is its high treatment cost, which limits accessibility across both developed and emerging healthcare systems. As a biologic therapy requiring long-term administration for chronic immune thrombocytopenia, it places a considerable financial burden on patients and healthcare providers. For example, in price-sensitive regions, many patients rely on alternative therapies or discontinue treatment due to affordability issues, directly reducing prescription volumes and revenue growth. Limited insurance coverage and inconsistent reimbursement policies further restrict adoption in public healthcare systems. This cost barrier slows market penetration and shifts demand toward lower-cost thrombopoietin receptor agonist alternatives, impacting overall market expansion.
03

Opportunity: Expanding pediatric immune thrombocytopenia treatment across developed and emerging healthcare systems and Increasing adoption of biologic thrombocytopenia therapies in chronic disease management programs globally

A key opportunity for romiplostim lies in the expanding treatment of pediatric immune thrombocytopenia, particularly in hospitals and specialized hematology centers. Increasing diagnosis rates among children aged one year and above are driving demand for safer, targeted biologic therapies. Physicians are increasingly adopting romiplostim as a second-line treatment when conventional therapies fail, due to its ability to improve platelet counts without long-term immunosuppression. Growing awareness among parents and improved pediatric hematology infrastructure in emerging economies are further supporting adoption. This segment is expected to see strong growth, especially in North America, Europe, and rapidly developing Asia-Pacific healthcare systems.
Romiplostim presents strong opportunities in chronic immune thrombocytopenia management programs as healthcare systems shift toward biologic-based long-term disease control. Hospitals and specialty clinics are increasingly integrating thrombopoietin receptor agonists into standard treatment pathways for refractory ITP patients. This shift is driven by improved clinical outcomes, reduced bleeding risks, and better patient quality of life. Strategic collaborations between pharmaceutical companies and healthcare providers are expanding access to advanced biologics. Developed regions, particularly the United States and Western Europe, are leading adoption, while emerging markets are gradually incorporating romiplostim into public and private healthcare treatment protocols for chronic hematologic conditions.
04

Challenge: Availability of alternative thrombopoietin receptor agonists reducing romiplostim market share expansion

Another key restraint is the increasing availability and clinical adoption of alternative thrombopoietin receptor agonists such as eltrombopag, which provide oral administration and broader convenience. These alternatives are often preferred in certain treatment settings due to ease of use and lower administration complexity compared to injectable biologics like romiplostim. For instance, physicians may choose oral therapies for long-term outpatient management, especially in resource-constrained healthcare environments. This substitution effect reduces romiplostim’s market share growth potential and intensifies competitive pressure within the ITP treatment landscape. As treatment guidelines continue to evolve, the presence of multiple effective alternatives limits exclusive reliance on romiplostim and moderates its overall demand trajectory.

Supply Chain Landscape

1

Raw Material Suppliers

Allegra CompanySigma Aldrich
2

Primary Producers

Amgen IncOctapharma
3

Secondary Producers & Distributors

GL Pharma GmbHPanacea Biotec
4

Industry

HospitalsBlood Donation Centers
Romiplostim - Supply Chain

Use Cases of Romiplostim in Chronic Immune Thrombocytopenia Management & Pediatric Immune Thrombocytopenia Treatment

Chronic Immune Thrombocytopenia Management : In chronic immune thrombocytopenia management, romiplostim is primarily used as a recombinant thrombopoietin receptor agonist administered through subcutaneous injection to stimulate platelet production in adults with persistent ITP. It is widely prescribed for patients who do not respond adequately to corticosteroids, immunoglobulins, or splenectomy. By activating megakaryocyte development in the bone marrow, it helps maintain safe platelet levels and reduces bleeding risks. Its long-term use supports sustained disease control, improving patient quality of life. Hematologists prefer romiplostim in chronic cases due to its targeted mechanism, predictable response, and ability to reduce dependency on immunosuppressive therapies.
Pediatric Immune Thrombocytopenia Treatment : In pediatric immune thrombocytopenia treatment, romiplostim is used in carefully adjusted low-dose injectable form for children aged one year and above who have chronic or refractory ITP. Pediatric hematologists administer it when first-line therapies fail to maintain adequate platelet counts. The drug is valued for its ability to enhance platelet production without long-term immunosuppression, making it suitable for younger patients. Its controlled dosing and favorable safety profile allow effective management of bleeding risks while supporting normal growth and activity. Increasing clinical adoption in pediatric hospitals reflects growing confidence in biologic therapies for childhood hematologic disorders.
Hepatitis C-Associated Thrombocytopenia : In hepatitis C-associated thrombocytopenia, romiplostim is used as a supportive therapy to manage low platelet counts that limit antiviral treatment options. It is administered as a subcutaneous biologic agent to stimulate platelet production in patients undergoing or preparing for hepatitis C therapy. By improving platelet levels, it enables safer initiation and continuation of antiviral regimens, including interferon-based and direct-acting antiviral treatments. This application is particularly important in patients with liver-related complications where thrombocytopenia restricts therapeutic choices. Clinical use of romiplostim in this segment is increasing as healthcare providers focus on improving treatment eligibility and outcomes in chronic hepatitis C cases.

Impact of Industry Transitions on the Romiplostim Market

As a core segment of the Pharmaceutical industry, the Romiplostim market develops in line with broader industry shifts. Over recent years, transitions such as Shift from conventional immunosuppressive therapies to targeted biologic platelet stimulation treatments and Transition toward long-term disease management and outpatient biologic treatment models in hematology care have redefined priorities across the Pharmaceutical sector, influencing how the Romiplostim market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift from conventional immunosuppressive therapies to targeted biologic platelet stimulation treatments

The romiplostim market is witnessing a major transition from traditional immunosuppressive therapies and short-term platelet-boosting treatments toward targeted biologic approaches such as thrombopoietin receptor agonists. Healthcare providers are increasingly preferring romiplostim for chronic immune thrombocytopenia due to its ability to directly stimulate platelet production rather than broadly suppressing the immune system. For example, hospitals are gradually reducing reliance on corticosteroids in long-term ITP management. This transition is improving patient outcomes, reducing relapse dependency, and reshaping treatment protocols in hematology, particularly in specialized care centers and tertiary hospitals.
02

Transition toward long-term disease management and outpatient biologic treatment models in hematology care

Another key transition is the shift from episodic hospital-based treatment to long-term outpatient disease management models in hematology. Romiplostim supports this change by enabling sustained platelet control through scheduled subcutaneous administration outside inpatient settings. For instance, specialty clinics are increasingly managing chronic ITP patients through outpatient biologic therapy programs, reducing hospitalization frequency and healthcare burden. This transition is enhancing patient convenience, improving continuity of care, and optimizing healthcare resource utilization. It is also encouraging broader adoption of biologics in ambulatory care settings across developed healthcare systems.